SAB Biotherapeutics (SABS) Net Income towards Common Stockholders (2021 - 2026)

SAB Biotherapeutics has reported Net Income towards Common Stockholders for 6 years, with the latest figure at -$18.9 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 263.09% year-over-year to -$18.9 million; the trailing twelve-month figure through Mar 2026 stood at -$56.2 million (down 63.91% YoY), and the FY2025 full-year result was -$47.8 million, down 40.04% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$18.9 million, down from -$15.1 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $985863.0 in Q1 2022, with the low at -$22.9 million in Q4 2023.
• Historically, Net Income towards Common Stockholders has averaged -$9.2 million across 5 years, with a median of -$7.4 million in 2023.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders sank 845.93% — and 2024, when it soared 50.15%.
• SAB Biotherapeutics' Net Income towards Common Stockholders stood at -$7.9 million in 2022, then plunged by 190.26% to -$22.9 million in 2023, then soared by 50.15% to -$11.4 million in 2024, then sank by 32.81% to -$15.1 million in 2025, then dropped by 24.69% to -$18.9 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$18.9 million (Q1 2026), -$15.1 million (Q4 2025), and -$12.1 million (Q3 2025), per Business Quant data.